A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.

被引：0
|
作者：
Kelly, William Kevin
Hussain, Arif
Saraiya, Biren
Thanigaimani, Pradeep
Sun, Furong
Seebach, Frank A.
Lowy, Israel
Sandigursky, Sabina
Miller, Elizabeth
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA USA
[2] Univ Maryland, Med Ctr, Baltimore, MD USA
[3] Rutgers State Univ, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA
[4] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS284
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer
    Kelly, William Kevin
    Thanigaimani, Pradeep
    Sun, Furong
    Seebach, Frank A.
    Lowy, Israel
    Sandigursky, Sabina
    Miller, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer.
    Zhang, Jingsong
    Stein, Mark N.
    Kelly, William Kevin
    Tsao, Che-Kai
    Falchook, Gerald Steven
    Xu, Yuanfang
    Seebach, Frank A.
    Lowy, Israel
    Mohan, Kosalai Kal
    Kroog, Glenn
    Miller, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [3] A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer.
    Drake, Charles G.
    Zhang, Jingsong
    Stein, Mark N.
    Xu, Yuanfang
    Seebach, Frank A.
    Lowy, Israel
    Mohan, Kosalai Kal
    Kroog, Glenn
    Miller, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Updated results on the bispecific PSMAxCD3 antibody CC-1 for treatment of prostate cancer.
    Heitmann, Jonas S.
    Hackenbruch, Christopher
    Walz, Juliane S.
    Jung, Susanne
    Pfluegler, Martin
    Schlenk, Richard F.
    Ochsenreither, Sebastian
    Hadaschik, Boris A.
    Darr, Christopher
    Jung, Gundram
    Salih, Helmut R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Preliminary results from a phase 1/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Stein, Mark N.
    Zhang, Jingsong
    Kelly, William Kevin
    Wise, David R.
    Tsao, Kai
    Carneiro, Benedito A.
    Falchook, Gerald Steven
    Sun, Furong
    Govindraj, Shilpa
    Sims, Jennifer S.
    Zhu, Min
    Seebach, Frank A.
    Lowy, Israel
    Thanigaimani, Pradeep
    Sandigursky, Sabina
    Miller, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [6] Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma
    Heitmann, Jonas S.
    Walz, Juliane S.
    Pfluegler, Martin
    Kauer, Joseph
    Schlenk, Richard F.
    Jung, Gundram
    Salih, Helmut R.
    BMJ OPEN, 2020, 10 (10):
  • [7] Results of the First Application Study of CC-1, a bispecific PSMAxCD3 Antibody, in Patients with Prostate Cancer
    Hackenbruch, C.
    Heitmann, J. S.
    Walz, J. S.
    Pfluegler, M.
    Marconato, M.
    Tegeler, C. M.
    Reusch, J.
    Labrenz, J.
    Schlenk, R. F.
    Jung, G.
    Salih, H. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 186 - 187
  • [8] A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
    Shore, Neal D.
    Mellado, Begona
    Shah, Satish
    Hauke, Ralph J.
    Costin, Dan
    Morris, Thomas
    Anjum, Rana
    Szijgyarto, Zsolt
    Verheijen, Remy B.
    Cullberg, Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [9] Phase I study of entinostat in combination with enzalutamide for treatment of patients with castration-resistant prostate cancer.
    Lin, Jianqing
    Elkon, Jacob Matt
    Ricart, Brittany
    Burgess, Brooke
    Palmer, Erica
    Siegel, Robert S.
    Ma, Yan
    Villagra, Alejandro
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [10] A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345